- KR₩76bn
- KR₩93bn
- KR₩137bn
- 44
- 71
- 48
- 56
Annual balance sheet for Yuyu Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 26,967 | 20,615 | 50,263 | 30,778 | 32,354 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 20,500 | 20,004 | 22,793 | 24,816 | 24,455 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 65,054 | 64,467 | 98,888 | 96,358 | 101,597 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 63,263 | 78,073 | 80,341 | 81,371 | 81,403 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 137,719 | 154,901 | 192,985 | 195,205 | 198,214 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 42,496 | 18,399 | 30,015 | 64,316 | 49,975 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 49,024 | 40,542 | 68,704 | 78,389 | 86,026 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 88,695 | 114,359 | 124,281 | 116,816 | 112,188 |
Total Liabilities & Shareholders' Equity | 137,719 | 154,901 | 192,985 | 195,205 | 198,214 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |